TABLE 5.
Comparison of model estimates of diagnostic performance for different screening methods using pure culturesa
| Method (no. of studies) | Sensitivity (%) (95% CI) | Specificity (%) (95% CI) | DOR (95% CI) | Aggregate no. of isolates (no. of positive isolates) |
|---|---|---|---|---|
| Brilliance CRE (4) | 81.3 (77.1–84.88) | 58.89 (39.31–76.02) | 6.23 (2.6–14.91) | 774 (439) |
| CDC protocol for ertapenem (1) | 79.23 (71.21–85.47) | 68.57 (30.95–91.4) | 8.32 (1.49–46.57) | 200 (130) |
| CDC protocol for meropenem (1) | 46.92 (38.24–55.8) | 78.57 (42.41–94.81) | 3.24 (0.58–18.19) | 200 (130) |
| CHROMagar KPC (2) | 42.11 (35.69–48.81) | 78.13 (52.18–92.12) | 2.6 (0.73–9.27) | 318 (228) |
| chromID Carba (1) | 90.77 (84.36–94.72) | 88.57 (59.31–97.63) | 76.21 (11.97–485.11) | 200 (130) |
| chromID ESBL (2) | 91.01 (86.26–94.23) | 21.27 (7.95–45.8) | 2.74 (0.75–9.95) | 376 (244) |
| Colorex KPC (2) | 52.45 (45.78–59.04) | 59.13 (32.06–81.6) | 1.6 (0.48–5.35) | 377 (230) |
| Supercarba (3) | 96.27 (93.53–97.87) | 60.38 (37.33–79.59) | 39.29 (12.52–123.33) | 176 (114) |
a
CI, confidence interval; DOR, diagnostic odds ratio.